Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

NCT03529448 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Neurooncología as lead sponsor.

NCT NCT03529448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03529448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Lead sponsor
Grupo Español de Investigación en Neurooncología
Phase
Phase 1/2
Overall status
Completed
Start date
August 18, 2023
Completion date
November 13, 2025
Enrollment
33 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma